TMCnet News
Tarveda to Present on Lead Intracellular Targeting Pentarin PEN-866 at 2017 American Association of Pharmaceutical Scientists National Biotechnology ConferenceTarveda Therapeutics, Inc., a clinical stage biopharmaceutical company discovering and developing Pentarins™ as a new class of potent and selective cancer medicines, today announced that Dr. Mark Bilodeau, PhD, Senior Vice President of Chemistry, will present data on PEN-866, the company's second Pentarin™ drug candidate which targets the intracellular protein HSP90, at the 2017 American Association of Pharmaceutical Scientists (AAPS) National Biotechnology Conference, occurring May 1-3 at the San Diego Marriott Marquis and Marina in San Diego, CA (News - Alert). The presentation, titled "Exploiting the preferential accumulation of HSP90-targeting ligands in tumors to selectively deliver anti-cancer payloads" will take place from 10:40am - 11:10am PST on Monday, May 1st 2017 in the 'Hot Topic' session Inaugurating a New Era in Cancer Treatment-Intracellular Delivery. "Dr. Bilodeau's presentation at AAPS continues to showcase our growing expertise in identifying and developing our Pentarins, potent and selective miniaturized drug conjugates that safely and effectively target anti-cancer payloads to solid tumors," said Drew Fromkin, President and Chief Executive Officer of Tarveda. "The presentation will highlight our lead intracellular targeting conjugate, PEN-866, that binds to the intracellular target HSP90. In a broad range of tumor xenograft and patient-derived tumor models, PEN-866 demonstrated accumulation and retention of its potent payload SN-38 leading to cancer cell death and efficacy, which was clearly superior to tht which was seen with irinotecan. We are excited about the prospects of PEN-866 and the potential to leverage our HSP90 franchise to enhance the performace of a number of high value payloads that have struggled to achieve efficacy in patients as single agents." PEN-866, which is designed to treat patients with solid tumor cancers including colorectal cancer, small cell lung cancer and sarcoma, is scheduled to enter the clinic in 2017 via a Phase 1/2a trial initially focused in patients with Topo-1 Inhibitor sensitive solid tumors. More information on PEN-866 can be found at www.tarveda.com.
About Pentarins™
About Tarveda Therapeutics
View source version on businesswire.com: http://www.businesswire.com/news/home/20170428005805/en/ |